



FCF Fox Corporate Finance | FCF Life Sciences  
**Life Sciences Venture Capital Monitor – Europe**


*March 2023*

*Antibody*



THE FINANCING SPECIALIST

**FCF LIFE SCIENCES  
OVERVIEW**



## Overview



### Focus on Biotech, MedTech and HealthTech

We advise innovative companies on arranging, structuring and placing equity, debt, and licensing transactions in a holistic financing approach



### Focus Areas

FCF advises on the following transaction types:



**FCF Life Sciences**  
advises leading Life Sciences companies in Europe in financing transactions

Over **EUR 2bn** Life Sciences transaction volume  
(Professionals and Advisors)

Life Sciences Team of **>12**

Over **100** years in aggregated Life Sciences experience

Access to **> 1,500** international investors

**Company Valuation**  
in partnership with **BioScience Valuation GmbH**

**China Licensing**  
in partnership with **YAFO Capital**

**Leading** EIB advisor in Europe

Over **80** completed Life Sciences transactions  
(Professionals and Advisors)

**8** regularly published Life Sciences reports

## Life Sciences Team



**Dr. Alexandra Goll**  
Advisor – Venture Capital



**Dr. Axel Polack**  
Advisor – Science & Technology



**Claus Schalper**  
Advisor – Corporate Affairs



**Dr. Mathias Schott**  
Advisor – Life Sciences



**Johannes Link**  
Life Sciences Banking – Europe



**Marcel Christou**  
Life Sciences Banking – Europe



**Enno Spillner**  
Advisor – Capital Markets



**Dr. Joachim M. Greuel**  
Advisor – Valuations



**Prof. Dr. Horst Domdey**  
Advisor – Science & Technology



**Zaid Maleh**  
Life Sciences Banking – Dubai



**Sean Jian, CFA**  
Life Sciences Banking – China



## Services

- ✓ Integrated Financial Modelling
- ✓ Investor Screening
- ✓ Management Presentation
- ✓ Post-Transaction Support
- ✓ Due Diligence Support
- ✓ Financing Strategy Advisory
- ✓ Investor / IR Roadshow
- ✓ Equity & Debt Fundraising
- ✓ Term Sheet Negotiation
- ✓ Life Science Advisory Board
- ✓ Closing Assistance
- ✓ IPO Execution Support

(extract from service portfolio)



## Our capital markets research feeds our proprietary investor database

### Data Collection

#### Life Sciences Venture Capital Monitor – Europe



- Venture Capital
- Life Sciences\*
- Focus on Europe

#### Biotech Venture Capital Monitor – US



- Venture Capital
- Life Sciences
- Focus on the US

#### Life Sciences Venture Capital Report



- Venture Capital
- Life Sciences
- Focus on Europe and the US

#### Biotech Licensing Monitor – China



- Licensing
- Biotech
- Focus on Europe and Chinese licensors

#### Biotech Public Equity Monitor



- Public Equity
- Biotech
- Focus on Europe

#### MedTech Public Equity Monitor



- Public Equity
- MedTech
- Focus on Europe

#### Life Sciences IPO Report



- IPOs
- Life Sciences
- Focus on Europe and the US

#### Life Sciences SPAC Monitor



- SPACs
- Life Sciences
- Focus on US / Europe and US SPACs


### Market Monitoring

#### Data Processing

- Transaction data
- Investment preferences

#### Proprietary Investor Database

- Most comprehensive database
- > 1,300,000 data points



#### Constant Data Enrichment

- Ongoing investor communication
- Data validation



#### Data-driven Investor Selection

1  
2  
3

- Intelligent search algorithms
- Big data sequencing

# Executive Summary

*The FCF Life Sciences Venture Capital Monitor - Europe is a monthly published overview focusing on the venture capital financing environment in the Biotech, Pharmaceutical, MedTech and HealthTech segments, and can be used as a quick reference for investors, corporates and professionals*

*More advanced, detailed and / or customized reports are available upon request*

## FCF Life Sciences Venture Capital Monitor - Europe

is a monthly published overview of Biotech, Pharmaceutical, MedTech and HealthTech companies, displaying venture capital financing trends in the European life science industry

### Scope

The selection of companies is based on the following criteria:

- Focus on transactions with European headquartered life science companies and available deal volume
- Companies operating in the Biotech, Pharmaceutical, MedTech, HealthTech, Services or other life science related sectors
- The Biotech sector is further divided into the following therapy areas / indications: Cardiovascular, Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders, Immunology, Infectious Disease, Male Health, Metabolic Disorders, Mouth and Dental Disorders, Musculoskeletal, Non Malignant Disorders, Nutritional Disorders, Oncology, Ophthalmology, Respiratory, Toxicology, Women's Health

*To recommend colleagues or fellow investors to be added to the mailing list, kindly send an email with the respective contact information*

## Recipients

The FCF Life Sciences Venture Capital Monitor - Europe targets the following recipients:

- Corporates / Executives
- Institutional investors
- Private equity investors
- Venture capital investors
- Family Offices / High-net-worth individuals
- Advisors

## Availability

The FCF Life Sciences Venture Capital Monitor - Europe is available on FCF's website at "<https://www-fcf-de/de/life-sciences/>"

## Data

All input data is provided by Pitchbook or GlobalData and is not independently verified by FCF- Ratio and multiple calculations are driven based on the input data available- For additional information and disclaimer, please refer to the last page

*If you have questions, comments or ideas, please do not hesitate to contact us*



Agenda

---


**EUROPEAN VENTURE CAPITAL  
TRANSACTIONS IN LIFE SCIENCES**

MARCH 2023




### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	Amolyt Pharma	FR	130	C
2	Hemab Therapeutics	DK	125	B
3	Noema Pharma	CH	104	B
4	Ascend Gene And Cell Therapies	UK	62	B
5	Companion Spine	FR	56	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	European Innovation Council Fund	DE	41	7
2	Flerie Invest	SE	39	1
3	Novo Holdings	DK	35	3
4	Andera Partners	FR	28	3
5	Gilde Healthcare Partners	DE	27	2

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
1	31-03-2023	Bluedrop Medical	IRL	MedTech	Diabetic Detection Device / Undisclosed	Developer of a diabetic detection device designed to detect diabetic foot ulcers early.	C	11	16	The company raised EUR 10.5 million of venture funding on March 31, 2023. The funds will be used to complete clinical trials and initiate product commercialization, expand the company's production capacity and to create 25 new jobs in product development and commercial teams.
2	30-03-2023	Smart Immune	FRA	Biotech / Pharma	Immunology / Phase I	Operator of a biotechnology company intended to focus on delivering the rapid, multi-potent curative power of T Cell Progenitors to reboot the immune system.	-	18	17	The company joined an Accelerator on March 30, 2023 and received EUR 17.5 million in funding. Out of the total funding EUR 2.5 million was received in the form of grant. The funds will be used for CAR T-cell application development of the ProTcell platform and bioproduction scale-up.
3	30-03-2023	Aurealis Therapeutics	CHE	Biotech / Pharma	Metabolic Disorders / Phase II	Developer of a gene therapy platform designed to focus on immune microenvironment modulation for a durable systemic anti-cancer response.	A	9	28	The company raised \$10 million of Series A venture funding on March 30, 2023. The funds will be used to advance the lead product AUP-16, start Phase 2 clinical trial in Diabetic Foot Ulcer (DFU) and begin preparations for clinical trials in Venous Leg Ulcer and Pressure Ulcer.
4	30-03-2023	Abi Global Health	IRL	HealthTech	Medical Application / On Market	Developer of a messenger-based application designed to get health advice from actual doctors.	A	5	5	The company raised EUR 4.6 million of Series A venture funding on March 30, 2023. The funds will be used to continue the company's expansion into additional markets to meet the needs of its local, regional and global clients.
5	30-03-2023	Okomera	FRA	MedTech	Medical Device / Developing	Developer of medical technologies designed to accelerate the development of modern cancer therapies with microfluidic 3D cellular assays.	-	< 1	< 1	The company received \$200,000 on March 30, 2023.
6	28-03-2023	deepc	DEU	HealthTech	AI Radiology System / On market	Developer of radiology AI operating system designed to support radiologists and their patients.	A	12	16	The company raised EUR 12 million of Series A venture funding on March 28, 2023. The funds will be used to develop new product innovations and to extensively commercialize its proprietary AI operating system which enables the integration of AI into radiological workflows.
7	28-03-2023	Kayentis	FRA	HealthTech	Clinical Data Platform / On market	Developer of electronic clinical outcome assessment (eCOA) technology designed to offer new perspectives to speed up clinical trials.	G	5	27	The company raised EUR 5 million through the combination of debt and venture funding on March 28, 2023.
8	27-03-2023	SolasCure	GBR	Biotech / Pharma	Dermatology / Phase I	Developer of healthcare technology designed to leverage biomimicry and evidence-based medicine to treat patients with chronic wounds.	B	12	30	The company raised GBP 10.9 million of Series B venture funding on March 27, 2023.


Source: PitchBook as of 16-04-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	Amolyt Pharma	FR	130	C
2	Hemab Therapeutics	DK	125	B
3	Noema Pharma	CH	104	B
4	Ascend Gene And Cell Therapies	UK	62	B
5	Companion Spine	FR	56	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	European Innovation Council Fund	DE	41	7
2	Flerie Invest	SE	39	1
3	Novo Holdings	DK	35	3
4	Andera Partners	FR	28	3
5	Gilde Healthcare Partners	DE	27	2

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
9	26-03-2023	Swing (Enterprise Systems)	FRA	HealthTech	Medical Management Application / Undisclosed	Developer of a medical management application designed to offer medical replacements from research to payment with accounting and administrative support.	-	< 1	< 1	The company raised EUR 421,000 of equity crowdfunding on March 26, 2023.
10	26-03-2023	Clandev	POL	MedTech	Medical Device / Undisclosed	Developer of devices designed to remove blockages from the venous sinuses in the brain.	A	< 1	< 1	The company raised PLN 1 million of venture funding on March 26, 2023.
11	24-03-2023	Notify Therapeutics	DNK	Biotech / Pharma	Women's Health / Undisclosed	Developer of therapeutics intended to treat infertile women.	A	< 1	1	The company joined an Accelerator on March 24, 2023 and received DKK 5.8 million in funding.
12	23-03-2023	Companion Spine	FRA	MedTech	Medical Implant / On market	Operator of a spine care company intended to provide diagnostic and medical implant products.	A	56	56	The company raised \$60.1 million of Series A venture funding on March 23, 2023. The funds will be used to supports the comprehensive solutions portfolio that precisely addresses, over time, the different stages and the multiple origins of back pain.
13	23-03-2023	Lunaphore Technologies	CHE	MedTech	Medical Device / On Market	Developer of a tumor analysis platform designed to perform assays much faster than standard techniques.	1	40	76	The company raised CHF 40 million through a combination of debt and Series D1 venture funding on March 23, 2023, putting the company's pre-money valuation at an estimated CHF 261.60 million. The funds will be used to strengthen its growing portfolio offering in spatial biology as well as support commercial execution to address ever-growing demand from customers.
14	23-03-2023	Mbiomics	DEU	Biotech / Pharma	Other / On Market	Operator of a microbiome research firm intended to transform microbiome research, diagnostics, and therapeutics.	A	13	13	The company raised EUR 13 million of Series A venture funding on March 23, 2023. The funds will be used to build the company's platform, accelerate the identification of the first lead drug candidates, and speed up the research efforts toward clinical validation.
15	23-03-2023	MVision	FIN	HealthTech	Medical Software / On Market	Developer of automatic segmentation and contouring software designed to streamline cancer treatment planning.	A	6	8	The company raised EUR 5.65 million of venture funding on March 23, 2023, putting the company's pre-money valuation at EUR 18.25 million. The funds will be used to research and development of new solutions to speed treatment planning for radiotherapy and build a globally scalable cloud-based platform for cancer treatment.
16	23-03-2023	Smi Drug Discovery	GBR	Biotech / Pharma	Other / Undisclosed	Manufacturer of a discovery tool designed to allow scientists to determine key components of drug-receptor interactions.	C	< 1	6	The company raised GBP 430,108 of venture funding on March 23, 2023, putting the company's pre-money valuation at GBP 7.73 million.

Source: PitchBook as of 16-04-2023; FCF Equity Research


Note: All volumes in EURm; financing rounds without deal values are excluded

<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)




### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	Amolyt Pharma	FR	130	C
2	Hemab Therapeutics	DK	125	B
3	Noema Pharma	CH	104	B
4	Ascend Gene And Cell Therapies	UK	62	B
5	Companion Spine	FR	56	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	European Innovation Council Fund	DE	41	7
2	Flerie Invest	SE	39	1
3	Novo Holdings	DK	35	3
4	Andera Partners	FR	28	3
5	Gilde Healthcare Partners	DE	27	2

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
17	23-03-2023	Strominnate Therapeutics	SWE	Biotech / Pharma	Oncology / Undisclosed	Operator of a biotech company intended to provide treatment for tumors and conditions of the nervous system.	A	< 1	< 1	The company raised SEK 3 million of venture funding on March 23, 2023. The funds will be used by the company to increase its investments in building the team, selecting the drug candidate and choosing the best regulatory path forward.
18	21-03-2023	Qida	ESP	Healthcare Services	Home Care Services / On market	Provider of home care services intended to serve the elderly and dependent people.	C	18	6	The company raised EUR 18 million of venture funding in the form of convertible debt on March 21, 2023. The funds will be used to grow and improve the technological product, as well as to prepare for international expansion.
19	21-03-2023	Sirius Medical	NLD	MedTech	Tumor Detection Device / On market	Developer of tumor localization technology designed to improve care for cancer patients.	B	12	16	The company raised EUR 12 million of Series B venture funding on March 21, 2023. The funding will be used to accelerate the worldwide growth of their product and support further product development.
20	20-03-2023	Vitestro Holding	NLD	MedTech	Medical Robotic Devices / Undisclosed	Developer of medical robotic devices designed for use in hospitals and clinical laboratories.	A	12	12	The company raised EUR 12 million of Series A venture funding on March 20, 2023.
21	20-03-2023	CellProthera	FRA	Biotech / Pharma	Cardiovascular / Phase II	Operator of a medical biotech company intended to develop cell therapies for heart muscles.	G	10	54	The company raised EUR 10.01 million of venture funding on March 20, 2023, putting the company's pre-money valuation at EUR 81.08 million. The funds will be used to accelerate the company's development of technology, which will be used in regeneration of heart muscle from blood stem cells.
22	20-03-2023	Gearbox Biosciences	EST	Biotech / Pharma	Other / Undisclosed	Developer of a robust technology designed to control bacterial growth with high precision.	A	< 1	< 1	The company raised EUR 125,000 of venture funding on March 20, 2023.
23	20-03-2023	MX Labs	EST	HealthTech	Health Application / On Market	Developer of artificial intelligence (AI) based health diagnostic tools designed for self-diagnosis and monitoring of hypertension.	-	< 1	2	The company joined an Accelerator on March 20, 2023 and received EUR 100,000 in funding.
24	17-03-2023	JuliaOmix	ITA	HealthTech	Digital Healthcare Platform / Undisclosed	Developer of a digital healthcare platform designed to offer an ecosystem of artificial intelligence-powered technologies for genetic analysis and clinical decision support for diseases.	A	1	3	The company raised EUR 1.15 million of venture funding on March 17, 2023.


Source: PitchBook as of 16-04-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	Amolyt Pharma	FR	130	C
2	Hemab Therapeutics	DK	125	B
3	Noema Pharma	CH	104	B
4	Ascend Gene And Cell Therapies	UK	62	B
5	Companion Spine	FR	56	A


#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	European Innovation Council Fund	DE	41	7
2	Flerie Invest	SE	39	1
3	Novo Holdings	DK	35	3
4	Andera Partners	FR	28	3
5	Gilde Healthcare Partners	DE	27	2


#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
25	15-03-2023	Avextra	DEU	Biotech / Pharma	Other / Undisclosed	Developer of cannabis-based medicines intended to treat symptoms of various diseases.	C	17	24	The company raised an estimated EUR 17 million of venture funding in the form of convertible debt on March 15, 2023. The funds will be used to expand sales and distribution channels of the company's product portfolio into new European markets, expedite Cannabis-based medication clinical trials, advance its R&D activities as well as further its expansion into the German market.
26	15-03-2023	Perspectum	GBR	HealthTech	Digital Healthcare Technology / On market	Developer of a digital healthcare technology designed to offer safe, non-invasive alternatives to traditional abdominal testing methods.	C	52	125	The company raised \$55 million of Series C venture funding on March 15, 2023. The funds will be used to further support the deployment, development, and validation of our platform-based product portfolio targeted for clinical research and clinical use.
27	15-03-2023	Fire1	IRL	MedTech	Monitoring Device / Undisclosed	Developer of a remote monitoring device designed to manage chronic diseases.	3	39	89	The company raised EUR 39.31 million of Series A3 venture funding on March 15, 2023. The funds will be used to accelerate the development of its novel remote monitoring solution to improve outcomes for heart failure patients.
28	15-03-2023	Inato	FRA	HealthTech	Clinical Trial Marketplace / On market	Operator of a global clinical trial marketplace intended to bring clinical research to each and every patient.	2	20	25	The company raised EUR 20.28 million through a combination of warrants and Series A2 venture funding on March 15, 2023, putting the company's pre-money valuation at EUR 55.82 million. The funds will be used to continue product innovation, international growth, and hiring of top talent.
29	15-03-2023	ZOE	GBR	Healthcare Services	Medical Testing Services / On market	Provider of medical testing services intended to deliver recommendations on personalized dietary plans for individuals.	D	2	95	The company raised \$2.5 million of venture funding on March 15, 2023. The funds will be used to scale the company's operations and science to bring the company to millions of people globally.
30	15-03-2023	Sophomer	CZE	Biotech / Pharma	Immunology / Undisclosed	Developer of synthetic polymers designed to serve as an alternative to the bovine serum albumin used in immunological assays.	A	< 1	< 1	The company raised estimated EUR 340,000 of venture funding on March 15, 2023. The funds will be used to further develop its technology, open a new laboratory in Prague 10, and expand its team with two new members.
31	15-03-2023	In-Teeth Technology	CHE	MedTech	Orthodontic Device / Undisclosed	Developer of a orthodontic apparatus device designed to treat malocclusion.	-	< 1	< 1	The company joined an Accelerator on March 15, 2023 and received CHF 10,000 in funding in the form of grant.
32	15-03-2023	Trojan Therapeutics	CHE	Biotech / Pharma	Oncology / Undisclosed	Developer of monocyte-based immunotherapy intended to develop the next generation of cell-based immunotherapy.	-	< 1	< 1	The company joined an Accelerator on March 15, 2023 and received \$10,000 in form of grant.

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	Amolyt Pharma	FR	130	C
2	Hemab Therapeutics	DK	125	B
3	Noema Pharma	CH	104	B
4	Ascend Gene And Cell Therapies	UK	62	B
5	Companion Spine	FR	56	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	European Innovation Council Fund	DE	41	7
2	Flerie Invest	SE	39	1
3	Novo Holdings	DK	35	3
4	Andera Partners	FR	28	3
5	Gilde Healthcare Partners	DE	27	2

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
33	14-03-2023	Teitur Tropics	DNK	Biotech / Pharma	Central Nervous System / Developing	Operator of medical research company intended to study small peptides involved in neurodegenerative diseases like Huntington's, Alzheimer's, and Parkinson's disease.	A	28	30	The company raised EUR 28.4 million series A of venture funding on March 14, 2023. Out of the total funding EUR 400,000 was raised in the form of convertible debt and subsequently converted to equity. The funds will be used to progress its lead drug candidate, TT-P34, from candidate selection into clinical development, including a Phase 1b clinical study in neurodegenerative diseases and to advance the preclinical program targeting neurodegenerative diseases.
34	14-03-2023	AlgoTherapeutix	FRA	Biotech / Pharma	Dermatology / Phase II	Operator of a biotechnology company designed to develop topical treatments for complex pain.	B	20	42	The company raised EUR 20 million of Series B venture funding on March 14, 2023. The funds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.
35	14-03-2023	HelloSelf	GBR	MedTech	Online Therapy / On market	Provider of online therapy and life coaching services intended to minimize the effects of stress.	B	17	27	The company raised GBP 14.7 million of Series B venture funding on March 14, 2023. The funds will be used to further grow its network of trusted therapists, members, and partners across the UK and Europe.
36	14-03-2023	Eventum Orthopaedics	GBR	MedTech	Medical Device / Undisclosed	Developer of a medical technology designed to improve the outcome for patients who have undergone knee replacement operations.	A	3	4	The company raised GBP 2.53 million of Series A venture funding on March 14, 2023, putting the company's pre-money valuation at GBP 5.98 million. The funds will be used by the company to begin production, expand its sales and technical team and apply for FDA approval in the US.
37	14-03-2023	Hapni	FRA	HealthTech	Online Screening Platform / On market	Developer of an online screening platform designed to prevent, diagnose and treat underdiagnosed diseases such as sleep apnea.	A	2	2	The company raised EUR 2 million of venture funding on March 14, 2023.
38	14-03-2023	OGD2 Pharma	FRA	Biotech / Pharma	Oncology / Undisclosed	Developer of innovative immunotherapies intended to target tumor-associated gangliosides.	E	2	6	The company raised EUR 1.64 million of venture funding on March 14, 2023, putting the company's pre-money valuation at EUR 12.91 million.
39	14-03-2023	Cognitant	GBR	HealthTech	Medical Insight Platform / On market	Developer of a medical insights platform intended to empower people with clear, reliable health information.	-	< 1	1	The company raised GBP 817,673 of angel funding on March 14, 2023, putting the company's pre-money valuation at GBP 7.36 million. The funding will be used to further develop its information platform and support new international clients.
40	14-03-2023	Les Audio-prothesistes Mobiles	FRA	MedTech	Hearing Device / On market	Manufacturer of a hearing device intended to improve the quality of life of dependent hearing people.	-	< 1	1	The company raised EUR 305,941 of angel funding on March 14, 2023, putting the company's pre-money valuation at EUR 2.00 million.


Source: PitchBook as of 16-04-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	Amolyt Pharma	FR	130	C
2	Hemab Therapeutics	DK	125	B
3	Noema Pharma	CH	104	B
4	Ascend Gene And Cell Therapies	UK	62	B
5	Companion Spine	FR	56	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	European Innovation Council Fund	DE	41	7
2	Flerie Invest	SE	39	1
3	Novo Holdings	DK	35	3
4	Andera Partners	FR	28	3
5	Gilde Healthcare Partners	DE	27	2

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
41	13-03-2023	Medwise.ai	GBR	HealthTech	Clinical AI Platform / On market	Operator of an artificial intelligence-powered, community-curated platform intended to offer clinical decision support to doctors.	B	1	3	The company raised GBP 1 million of venture funding on March 13, 2023. The funds will be used to scale up operations and strengthen the company's sales and marketing activities in the UK.
42	13-03-2023	Familidados	ESP	HealthTech	Caregiving Platform / On market	Operator of a caregiving platform intended to connect families and professional caregivers.	C	1	2	The company raised EUR 1 million of venture funding on March 13, 2023. The funds will be used to grow in volume and to refine the company's monetization mix.
43	13-03-2023	e-optalmo	FRA	HealthTech	Medical Platform / On market	Developer of a medical platform designed to provide a high-quality telemedicine experience to patients with visual health problems.	D	< 1	2	The company raised EUR 214,912 of venture funding on March 13, 2023, putting the company's pre-money valuation at EUR 3.17 million.
44	13-03-2023	intellithing	GBR	HealthTech	Digital Health Software / Developing	Developer of a digital health software designed to derive data from smart devices into fitness-related insights or predictions.	A	< 1	< 1	The company raised GBP 144,250 of venture funding on March 13, 2023, putting the company's pre-money valuation at GBP 1.5 million.
45	10-03-2023	MetaLead Therapeutics	CHE	Biotech / Pharma	Toxicology / Undisclosed	Developer of short peptides designed to tightly bind and detoxify Lead ions.	-	< 1	< 1	The company joined an Accelerator on March 10, 2023 and received CHF 140,000 in funding in the form of convertible debt. The funds will be used in the nationalization of the patent and in studies to obtain approval.
46	09-03-2023	Sunrise (Monitoring Equipment)	BEL	MedTech	Sleep Diagnose System / On Market	Developer of a clinically validated bio-signal designed to diagnose sleep apnea.	C	17	25	The company raised EUR 17 million of venture funding on March 9, 2023. The funds will be used to increase the company's size tenfold within 5 years.
47	09-03-2023	Ikos	FRA	HealthTech	Drug Designing Technology / On Market	Developer of a drug-designing technology designed to offer expertise in the field of ligand-based de novo design for multi-parameter optimization.	A	16	20	The company raised EUR 15.5 million of Series A venture funding on March 9, 2023. The funds will be used to expand the company's AI technology platform and launch Ikos Robotics; an AI-driven automated end-to-end drug discovery service.
48	09-03-2023	Complement Therapeutics	GBR	Biotech / Pharma	Ophthalmology / Undisclosed	Developer of a biotechnology platform intended to treat chronic diseases driven by the dysregulation of the complement system.	B	5	10	The company raised GBP 4.47 million of venture funding on March 9, 2023, putting the company's pre-money valuation at GBP 13.12 million.

Source: PitchBook as of 16-04-2023; FCF Equity Research


Note: All volumes in EURm; financing rounds without deal values are excluded

<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)




### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	Amolyt Pharma	FR	130	C
2	Hemab Therapeutics	DK	125	B
3	Noema Pharma	CH	104	B
4	Ascend Gene And Cell Therapies	UK	62	B
5	Companion Spine	FR	56	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	European Innovation Council Fund	DE	41	7
2	Flerie Invest	SE	39	1
3	Novo Holdings	DK	35	3
4	Andera Partners	FR	28	3
5	Gilde Healthcare Partners	DE	27	2

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
49	09-03-2023	Ocean Dx	FRA	MedTech	Molecular Diagnostic Kit / On Market	Developer of multiplexing molecular diagnostics kit designed to deliver quick diagnostic results.	A	1	1	The company raised EUR 1 million of venture funding on March 9, 2023. The funds will be used to grow its R&D teams and accelerate the development of a rapid test for the diagnosis of sepsis (sepsis) around which it will carry out a clinical study on a hundred patients in the fall.
50	09-03-2023	Soula	CYP	HealthTech	AI Healthcare Application / On market	Developer of an Artificial Intelligence based healthcare application designed to provide assistance pregnancy, birth and postpartum.	-	< 1	< 1	The company raised \$450,000 of angel funding on March 9, 2023.
51	08-03-2023	NunaBio	GBR	Biotech / Pharma	Other / Undisclosed	Developer of chemical and biological technologies and products based in England, United Kingdom.	A	2	2	The company raised GBP 1.75 million of venture funding on March 8, 2023, putting the company's pre-money valuation at GBP 1.60 million.
52	08-03-2023	CanSense	GBR	MedTech	Non-Invasive Blood Test / Undisclosed	Developer of an accurate and non-invasive blood test intended for early diagnosis of bowel cancer.	A	2	2	The company raised GBP 1.5 million of venture funding on March 8, 2023. The funds will be used to further develop the product and carry out clinical trials in order to meet regulatory requirements and bring it to market.
53	08-03-2023	NuVision Biotherapies	GBR	MedTech	Ophthalmic Therapy Product / On market	Developer, manufacturer, and seller of ophthalmic therapy products designed to address key clinical challenges facing ophthalmic surgeons.	A	1	8	The company raised GBP 1.1 million of venture funding on March 8, 2023. The funds will be used to accelerate the development of its first two products.
54	08-03-2023	Hermone	DEU	HealthTech	Femtech Application / On Market	Developer of femtech application designed for hormone cycle awareness.	-	1	1	The company raised EUR 1 million of angel funding on March 8, 2023.
55	08-03-2023	Sancare	FRA	HealthTech	Medical Data Analysis Software / On Market	Developer of data analysis software designed to automate the reporting of medical procedures.	A	1	5	The company raised EUR 1.16 million of venture funding on March 8, 2023, putting the company's pre-money valuation at EUR 12.15 million.
56	07-03-2023	Noema Pharma	CHE	Biotech / Pharma	Central Nervous System / Phase II	Developer of medical therapies designed to address the most disabling symptoms in orphan conditions of the brain and nervous system.	B	104	157	The company raised CHF 103 million of Series B venture funding on March 7, 2023, putting the company's pre-money valuation at an estimated CHF 142.02 million. The funds will be used for the continued development of its diversified pipeline focused on central nervous system disorders.


Source: PitchBook as of 16-04-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	Amolyt Pharma	FR	130	C
2	Hemab Therapeutics	DK	125	B
3	Noema Pharma	CH	104	B
4	Ascend Gene And Cell Therapies	GB	62	B
5	Companion Spine	FR	56	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	European Innovation Council Fund	DE	41	7
2	Flerie Invest	SE	39	1
3	Novo Holdings	DK	35	3
4	Andera Partners	FR	28	3
5	Gilde Healthcare Partners	DE	27	2

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
57	07-03-2023	NURISE	PRT	MedTech	Nuclear Radiation Sensors / Undisclosed	Developer of nuclear radiation sensors and equipment designed for research instrumentation and medical applications.	B	3	5	The company raised EUR 3.3 million of venture funding on March 7, 2023. The funds will be used to continue working on new projects, to internationalize solution, and, contribute to improving the quality of life of cancer patients all over the world.
58	05-03-2023	Alex Therapeutics	SWE	HealthTech	Therapeutic Application / On Market	Developer of therapeutic applications intended to democratize healthcare through psychology, design, and technology.	B	5	5	The company raised EUR 4.75 million of venture funding on March 5, 2023. The funds will be used by the company to accelerate the company's growth in Europe and the US and to develop novel DTX products alongside both new and existing partners.
59	03-03-2023	Meela	SWE	Healthcare Services	Mental Health Services / On Market	Provider of mental health services intended to offer personalized therapy to females by matching to fit therapists.	A	< 1	2	The company raised EUR 550,000 of venture funding on March 3, 2023. The funds will be used to invest in growth.
60	03-03-2023	Odimma Therapeutics	FRA	Biotech / Pharma	Oncology / Developing	Developer of immunotherapy drug designed to empower personalized immunotherapy to treat cancer.	A	< 1	2	The company raised EUR 963,184 of venture funding on March 3, 2023, putting the company's pre-money valuation at EUR 3.60 million.
61	02-03-2023	Biolog-id	FRA	HealthTech	Mapping System / Undisclosed	Developer of smart healthcare solution intended for the management and traceability of sensitive health products.	E	10	79	The company raised EUR 10.15 million of venture funding on March 2, 2023, putting the company's pre-money valuation at EUR 182.78 million.
62	02-03-2023	Hyvention	FRA	MedTech	Implantable Medical Device / On market	Operator of a medical company intended to develop implantable medical devices to address unmet clinical needs.	B	1	6	The company raised EUR 999,991 of venture funding on March 2, 2023, putting the company's pre-money valuation at EUR 15.80 million.
63	01-03-2023	Ascend Gene And Cell Therapies	GBR	Biotech / Pharma	Other / Undisclosed	Operator of a biotechnology firm designed for cell therapy design, development and manufacturing.	B	62	75	The company raised \$66.63 million of venture funding on March 1, 2023.
64	01-03-2023	Doctorly	DEU	HealthTech	Medical Practice Platform / On market	Developer of a medical practice platform designed for doctors to manage the whole process in one system.	A	9	17	The company raised \$10 million of Series A venture funding on March 1, 2023. The funds will be used to further accelerate the company's growth in the German market accelerating while it seeks to deliver new features and functionality aimed at reducing administrative costs and saving time to make work for healthcare professionals easier and faster.


Source: PitchBook as of 16-04-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	Amolyt Pharma	FR	130	C
2	Hemab Therapeutics	DK	125	B
3	Noema Pharma	CH	104	B
4	Ascend Gene And Cell Therapies	UK	62	B
5	Companion Spine	FR	56	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	European Innovation Council Fund	DE	41	7
2	Flerie Invest	SE	39	1
3	Novo Holdings	DK	35	3
4	Andera Partners	FR	28	3
5	Gilde Healthcare Partners	DE	27	2

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
65	01-03-2023	Porous	DEU	HealthTech	Microstructure Analysis System / Undisclosed	Operator of a health tech company intended for microstructure analysis of the cortical bone.	A	5	5	The company joined an Accelerator on March 1, 2023 and received EUR 5.1 million in funding.
66	01-03-2023	Antiverse	GBR	Biotech / Pharma	Other / Undisclosed	Operator of a drug discovery platform intended to predict antibody-antigen binding and provide antibody drug candidates in one day.	B	3	6	The company raised \$3 million of venture funding on March 1, 2023. The funds will be used to enable in-house development of the antibodies showing the highest affinity blocking function, making them ideal starting points as therapeutic assets.
67	01-03-2023	Ecq247	NOR	MedTech	Heart Rate Sensor / On market	Developer of a medically certified wireless heart rate sensor designed to continuously monitor the heart rhythm for investigation of heart rhythm disorders.	A	2	2	The company raised NOK 20 million of venture funding on March 1, 2023, putting the company's pre-money valuation at an estimated NOK 59.34 million.
68	01-03-2023	Sania Therapeutics	GBR	Biotech / Pharma	Central Nervous System / Developing	Developer of gene therapies intended to improve the quality of life of people with neurological diseases.	A	1	6	The company raised \$1.5 million of venture funding in the form of convertible debt on March 1, 2023.
69	01-03-2023	Medi2data	GBR	HealthTech	Healthcare Application / On market	Developer of healthcare technology designed for national health services to quickly and securely share consented patient information.	A	1	5	The company raised GBP 1.05 million of venture funding on March 1, 2023, putting the company's pre-money valuation at GBP 11.79 million.
70	01-03-2023	Anyo Labs	SWE	HealthTech	Drug Discovery Software / Undisclosed	Developer of Machine Learning software designed for faster and safer drug discovery.	A	< 1	< 1	The company raised SEK 200,000 of venture funding on March 1, 2023.

Source: PitchBook as of 16-04-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded

<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

# Contact Details & Disclaimer



## FCF Fox Corporate Finance GmbH

Maximilianstrasse 12-14 ▪ 80539 Munich ▪ Germany  
Telephone +49 (89) 206 0409-0 ▪ Facsimile +49 (89) 206 0409-299  
info@fcf.de ▪ www.fcf.de

### Arno Fuchs

*Chief Executive Officer*

P: +49 (89) 206 0409-100  
M: +49 (172) 863 6777  
arno.fuchs@fcf.de

### Dr. Mathias Schott

*Advisor Life Sciences*

P: +49 (89) 206 0409-123  
M: +49 (174) 301 1846  
mathias.schott@fcf.de

### Johannes Link

*Analyst*

P: +49 (89) 206 0409-150  
M: +49 (172) 839 5746  
johannes.link@fcf.de

### Marcel Louis Christou

*Junior Analyst*

P: +49 (89) 206 0409-127  
marcellouis.christou@fcf.de

## DISCLAIMER

This document does not constitute an offer or invitation to purchase or subscribe for any securities, and neither this document nor anything contained herein shall form the basis of or may be relied upon in connection with any contract or commitment whatsoever. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither FCF nor any of its officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. By accepting this document you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business. This document contains certain forward-looking statements, including assumptions, opinions and views cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein. FCF does not guarantee that the figures, assumptions and calculations underlying such historical and forward looking statements are free from errors nor does FCF accept any responsibility for the future accuracy of the opinions expressed in this document or the actual occurrence of the forecasted developments.

© FCF Fox Corporate Finance GmbH 2023





THE FINANCING SPECIALIST